DRUG-THERAPY - CANDIDATE AIDS VACCINES

被引：98

作者：

GRAHAM, BS

WRIGHT, PF

机构：

[1] VANDERBILT UNIV, SCH MED, DEPT PEDIAT, NASHVILLE, TN 37232 USA

[2] VANDERBILT UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, NASHVILLE, TN 37232 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 1995年 / 333卷 / 20期

关键词：

D O I：

10.1056/NEJM199511163332007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There is an urgent need to control the global epidemic of human immunodeficiency virus type 1 (HIV-1) infection. Although educational approaches to modify risk-taking behavior are a critical component of prevention, we focus this discussion on the status of vaccine development. The success of active immunization against other infectious diseases makes immunization an attractive approach to preventing HIV-1 infection. The eradication of smallpox1 and progress in the elimination of poliomyelitis, targeted to occur by the year 2000,2 are notable examples of the impact of vaccination. Given the complexity of HIV-1 pathogenesis, however, empirical approaches successful in the development of previous. © 1995, Massachusetts Medical Society. All rights reserved.

引用

收藏

页码：1331 / 1339

页数：9

相关论文

共 102 条

[1] THE IMMUNOLOGICAL PRINCIPLES OF VACCINATION [J].

ADA, GL .

LANCET, 1990, 335 (8688) :523-526

[2] INFECTION OF MACACA-NEMESTRINA BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].

AGY, MB ;

FRUMKIN, LR ;

COREY, L ;

COOMBS, RW ;

WOLINSKY, SM ;

KOEHLER, J ;

MORTON, WR ;

KATZE, MG .

SCIENCE, 1992, 257 (5066) :103-106

[3] CELLULAR PROTEINS BOUND TO IMMUNODEFICIENCY VIRUSES - IMPLICATIONS FOR PATHOGENESIS AND VACCINES [J].

ARTHUR, LO ;

BESS, JW ;

SOWDER, RC ;

BENVENISTE, RE ;

MANN, DL ;

CHERMANN, JC ;

HENDERSON, LE .

SCIENCE, 1992, 258 (5090) :1935-1938

[4] PATHOGENICITY OF LIVE, ATTENUATED SIV AFTER MUCOSAL INFECTION OF NEONATAL MACAQUES [J].

BABA, TW ;

JEONG, YS ;

PENNINCK, D ;

BRONSON, R ;

GREENE, MF ;

RUPRECHT, RM .

SCIENCE, 1995, 267 (5205) :1820-1825

[5] CONCURRENT EVOLUTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN PATIENTS INFECTED FROM THE SAME SOURCE - RATE OF SEQUENCE CHANGE AND LOW-FREQUENCY OF INACTIVATING MUTATIONS [J].

BALFE, P ;

SIMMONDS, P ;

LUDLAM, CA ;

BISHOP, JO ;

BROWN, AJL .

JOURNAL OF VIROLOGY, 1990, 64 (12) :6221-6233

[6] SAFETY AND IMMUNOGENICITY OF A FULLY GLYCOSYLATED RECOMBINANT GP160 HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VACCINE IN SUBJECTS AT LOW-RISK OF INFECTION [J].

BELSHE, RB ;

CLEMENTS, ML ;

DOLIN, R ;

GRAHAM, BS ;

MCELRATH, J ;

GORSE, GJ ;

SCHWARTZ, D ;

KEEFER, MC ;

WRIGHT, P ;

COREY, L ;

BOLOGNESI, DP ;

MATTHEWS, TJ ;

STABLEIN, DM ;

OBRIEN, FS ;

EIBL, M ;

DORNER, F ;

KOFF, W .

JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (06) :1387-1395

[7] INTERPRETING HIV SERODIAGNOSTIC TEST-RESULTS IN THE 1990S - SOCIAL RISKS OF HIV VACCINE STUDIES IN UNINFECTED VOLUNTEERS [J].

BELSHE, RB ;

CLEMENTS, ML ;

KEEFER, MC ;

GRAHAM, BS ;

COREY, L ;

SPOSTO, R ;

WESCOTT, S ;

LAWRENCE, D ;

GORSE, GJ ;

KENNEDY, D ;

FREY, S ;

LAMBERT, J ;

SCHWARTZ, D ;

DOLIN, R ;

ROBERTS, N ;

MCELRATH, J ;

COOMBS, J ;

WRIGHT, P ;

KARZON, D ;

FAST, P ;

WALKER, MC ;

MESTECKY, J ;

JACKSON, S ;

STABLEIN, D ;

WOLFF, M .

ANNALS OF INTERNAL MEDICINE, 1994, 121 (08) :584-+

[8] PROTECTION OF CHIMPANZEES FROM INFECTION BY HIV-1 AFTER VACCINATION WITH RECOMBINANT GLYCOPROTEIN GP120 BUT NOT GP160 [J].

BERMAN, PW ;

GREGORY, TJ ;

RIDDLE, L ;

NAKAMURA, GR ;

CHAMPE, MA ;

PORTER, JP ;

WURM, FM ;

HERSHBERG, RD ;

COBB, EK ;

EICHBERG, JW .

NATURE, 1990, 345 (6276) :622-625

[9] VIRUS-SPECIFIC CD8+ CYTOTOXIC T-LYMPHOCYTE ACTIVITY ASSOCIATED WITH CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].

BORROW, P ;

LEWICKI, H ;

HAHN, BH ;

SHAW, GM ;

OLDSTONE, MBA .

JOURNAL OF VIROLOGY, 1994, 68 (09) :6103-6110

[10] RELATION BETWEEN HIV-1 SYNCYTIUM INHIBITION ANTIBODIES AND CLINICAL OUTCOME IN CHILDREN [J].

BRENNER, TJ ;

DAHL, KE ;

OLSON, B ;

MILLER, G ;

ANDIMAN, WA .

LANCET, 1991, 337 (8748) :1001-1005

← 1 2 3 4 5 6 7 8 9 10 →